HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug, BGB-43395, that blocks a protein called CDK4 to slow cancer growth. It is for people with advanced hormone-positive, HER2-negative breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effe…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, ovarian, or lung cancer) that haven't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors, either alone or combine…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New combo pill aims to outsmart BRCA breast cancer
Disease control Recruiting nowThis study tests whether adding a new oral drug (elacestrant) to standard olaparib can help people with a specific type of advanced breast cancer (HR+, HER2-, with BRCA1/2 mutations) live longer without the disease getting worse. About 176 participants will receive either the com…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC